Tag: pneumococcal vaccine market forecast

  • Pneumococcal Vaccine Market Growth Potential: Key Insights for 2024-2033

    Pneumococcal Vaccine Market Growth Potential: Key Insights for 2024-2033

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    How Will the Pneumococcal Vaccine Market Grow from 2024 to 2033?

    The market size of the pneumococcal vaccine has seen significant growth in the past several years. It is projected to expand from $8.47 billion in 2023 to $9.04 billion in 2024, marking a compound annual growth rate (CAGR) of 6.7%. The upward trend during the historic period is a result of the identification of streptococcus pneumoniae, issues of public health, initiatives for early vaccination, progress in healthcare, and alterations in vaccine policies.

    In the coming years, robust growth is anticipated in the pneumococcal vaccine market. The market is set to expand to $11.36 billion by 2028, growing at a compound annual growth rate (CAGR) of 5.9%. The predicted growth during the forecast period can be credited to the evolution of pneumococcal strains, ongoing research and development activities, prioritizing immunization, increased access to vaccines, and aging population. The forecast period is also likely to see key trends such as the development of multivalent vaccines, targeted vaccination for high-risk groups, efforts to improve vaccine effectiveness, and campaigns to raise awareness and education, with a focus on immunization of infants.

    Claim Your Free Sample of the Global Pneumococcal Vaccine Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

    What Aspects Are Influencing the Growth Rate of the pneumococcal vaccine Market?

    The continued rise in the occurrence of pneumococcal infections is set to boost the pneumococcal vaccine market’s expansion. Pneumococcal infections are caused by a bacterium known as Streptococcus pneumoniae or pneumococcus, leading to pneumonia, bloodstream infections, ear, and sinus infections. The pneumococcal vaccine prompts the body to make antibodies against pneumococcal bacteria, reducing or eliminating bacteria and toxins that cause diseases, thus safeguarding children, the elderly, and individuals with compromised immune systems from various pneumococcal infections. For example, as of January 2022, Pneumococcal pneumonia, per the U.S. public health agency, the Center for Disease Control and Prevention, is responsible for approximately 150,000 hospitalizations annually in the U.S., contributing to almost 30% of adult community-acquired pneumonia. Consequently, the escalating incidence of pneumococcal complications stimulates the pneumococcal vaccine market’s progress.

    What Are the Critical Segments of the Pneumococcal Vaccine Market?

    1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

    2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

    3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

    4) By End User: Pediatrics, Adults

    What Trends Are Redefining Consumer Expectations in the Pneumococcal Vaccine Market?

    Reputed companies in the pneumococcal vaccine market are introducing new products to enhance their market profitability. An exemplary instance is that of Merck & Co Inc., an American pharmaceutical firm, which launched the V116 vaccine in July 2023. Intended to counter the eight unique serotypes of Streptococcus pneumoniae, the primary cause for adult pneumococcal disease, V116 outperforms other vaccines in terms of immunogenicity for various serotypes in adult demographics. It has also elicited strong immune responses in both individuals not previously vaccinated and those who have been. The notable V116 has received breakthrough therapy designation by the U.S. Food and Drug Administration (FDA), currently progressing into its Phase 3 development.

    Order Now for Fast Delivery of Your Pneumococcal Vaccine Market Report!

    https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

    What Are the Leading Regions in the Pneumococcal Vaccine Market Expansion?

    North America was the largest region in the pneumococcal vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    The Pneumococcal Vaccine Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the pneumococcal vaccine market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Pneumococcal Vaccine Market Include

    1. Pneumococcal Vaccine Market Executive Summary

    2. Pneumococcal Vaccine Market Segments

    3. Pneumococcal Vaccine Market Size And Template Market Growth Rate

    4. Key Pneumococcal Vaccine Market Trends

    5. Major Pneumococcal Vaccine Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Pneumococcal Vaccine Market

    26. Top Pneumococcal Vaccine Companies

    27. Pneumococcal Vaccine Market Opportunities And Strategies

    28. Pneumococcal Vaccine Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Pediatric Vaccine Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

    Adult Vaccines Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

    DTP Vaccines Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • What’s The Growth Forecast For Pneumococcal Vaccine Market Through 2024-2033?

    What’s The Growth Forecast For Pneumococcal Vaccine Market Through 2024-2033?

    The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

    Introduction

    • The pneumococcal vaccine market has witnessed robust growth in recent years.
    • Projected growth from $8.47 billion in 2023 to $9.04 billion in 2024 at a CAGR of 6.7%.

    Historic Growth Drivers

    • Discovery of Streptococcus pneumoniae.
    • Public health concern and early vaccination efforts.
    • Healthcare advancements and vaccine policy changes.

    Expected Growth in the Coming Years

    • Forecasted growth to $11.36 billion in 2028 at a CAGR of 5.9%.
    • Factors include evolving strains, research and development, and expanded vaccine access.

    View More On The Pneumococcal Vaccine Market Report 2024 – https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

    Major Trends in the Forecast Period

    • Multivalent vaccine development.
    • Targeted vaccination strategies.
    • Education and awareness campaigns.

    Rising Prevalence of Pneumococcal Contamination Drives Market Growth

    • Pneumococcal contamination encompasses various infections caused by Streptococcus pneumoniae.
    • The vaccine stimulates antibody production to combat these infections.
    • Increasing prevalence drives market growth, with significant hospitalization rates reported.

    Key Players in the Market

    • Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., among others.
    • Diverse range of companies contributing to vaccine development and distribution.

    Breakthrough in Vaccine Development

    • Merck & Co Inc. launched V116 vaccine targeting eight serotypes of Streptococcus pneumoniae.
    • V116 demonstrates superior immunogenicity in adult populations.
    • FDA designates V116 as a breakthrough therapy, currently in Phase 3 development.

    GSK Expands Vaccine Portfolio

    • GSK PLC’s acquisition of Affinivax, Inc. expands its vaccine offerings.
    • Access to MAPS technologies and 24-valent pneumococcal vaccine candidate.

    Market Segmentation

    1. Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products.
    2. Route of Administration: Intravenous, Intramuscular, Subcutaneous.
    3. Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Others.
    4. End User: Pediatrics, Adults.

    Regional Insights

    • North America led the market in 2023.
    • Asia-Pacific poised for rapid growth in the forecast period.

    Conclusion

    • The pneumococcal vaccine market shows substantial growth potential driven by increasing contamination prevalence and innovative vaccine development.
    • Collaboration among pharmaceutical companies and advancements in vaccine technology are key factors shaping the market’s trajectory.
    • With a focus on targeted vaccination strategies and expansion in emerging markets, the future of pneumococcal vaccine market appears promising.

    Request A Sample Of The Global Pneumococcal Vaccine Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=11950&type=smp